News | November 22, 2011

“Indiscriminate” Stenting for Asymptomatic Carotid Stenosis Addressed at VEITH Symposium

November 22, 2011 — The controversial subject of “indiscriminate” stenting to treat asymptomatic carotid stenosis (ACS) was addressed at the 38th annual VEITH Symposium. J. David Spence, M.D., professor of neurology and clinical pharmacology, University of Western Ontario, presented his findings. Spence is also director of the Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute.

The crux of the argument against stenting ACS is that the practice is based on historical risks of ACS that are no longer relevant. This is because optimized intensive medical treatment leads to lower risks of stroke or death; much of the practice that currently occurs is based on the results of the CREST trial that did not have a medical arm for comparison. Despite several investigators calling for a moratorium on stenting or surgery for ACS, the practice still continues, especially in the United States.

Because of this, Spence strongly stated, “There really is no question that indiscriminate intervention for ACS is ill-advised.” In situations with evidence of microemboli or multiple ulcers, CEA or CAS should be considered in the setting of a randomized trial that includes an intensive medical arm. The questions regarding malpractice or criminality are more extreme, but trying to answer them raise other important issues including financial motivation to continue to treat a condition where intervention or surgery is not warranted.

For more information: www.veithpress.org

Related Content

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable| September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular s
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Overlay Init